Biotech Values

[DewDiligence]

[MRK] previously played down the impact of a potential loss, saying its projection of long-term earnings growth would remain the same regardless of the outcome of the dispute.

I remember when MRK’s CFO said that on the CC announcing the planned merger with Schering-Plough. The statement did not ring true then and it still doesn’t. Give MRK’s lawyers credit for insisting on truthful disclosure of the importance of Remicade and Simponi in MRK’s SEC filing :- )